Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.

Danai DimaMichael HughesMark OrlandFauzia UllahUtkarsh GoelFaiz AnwerShahzad RazaSandra MazzoniDivaya BhutaniLouis WilliamsSuzanne LentzschChristy SamarasJason ValentRajshekhar ChakrabortyJack Khouri

Published in: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2024)

These findings are encouraging for the use of venetoclax as salvage therapy post-dara failure.

Keyphrases

multiple myeloma
stem cells
adipose tissue
skeletal muscle
weight loss